# A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)

> **NCT04138823** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 12 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** BI 891065

## Key facts

- **NCT ID:** NCT04138823
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-26
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138823, "A Study to Test Different Doses of BI 891065 Alone and in Combination With BI 754091 in Asian Patients With Different Types of Advanced Cancer (Solid Tumours)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04138823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*